Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
221 stopped studies mapped to Malignant Skin Neoplasm and descendants · 91% state a reason
Over the 221 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01663571 | STAT3 in T Cells: At The Crossroads of Inflammation and Cancer | — | terminated | Aug 13, 2012 | NYU Langone Health | Study is permanently closed to enrollment .Collection of private identifiable information is… | Enrollment / accrual |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | Phase 1 / Phase 2 | withdrawn | Sep 13, 2017 | University of Leeds | Withdrawn by Sponsor | Other (stated, no rule matched) |
| NCT01823679 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of… | Phase 2 | terminated | Apr 4, 2013 | Stanford University | Low accrual | Enrollment / accrual |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With… | Phase 1 / Phase 2 | withdrawn | Jun 24, 2016 | Joanne Jeter | poor accrual | Enrollment / accrual |
| NCT03235869 | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | Early Phase 1 | withdrawn | Aug 1, 2017 | University of Michigan Rogel Cancer Center | The company pulled durvalumab from heme malignancies | Sponsor / business decision |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | Phase 2 | terminated | Nov 15, 2013 | Nina Bhardwaj | PI discretion, low enrollment | Enrollment / accrual |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | Phase 1 / Phase 2 | terminated | Aug 24, 2010 | Stanford University | Business decision by funding source | Funding |
| NCT02076243 | Treatment With Nab-paclitaxel in Cutaneous SCC | Phase 2 | terminated | Mar 3, 2014 | Icahn School of Medicine at Mount Sinai | Closed by sponsor | Other (stated, no rule matched) |
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With… | Phase 2 | terminated | Apr 11, 2014 | National Cancer Institute (NCI) | Study terminated due to low accrual and change in research focus. | Enrollment / accrual |
| NCT02223975 | Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease(Vulval VS) | — | suspended | Aug 22, 2014 | Gloucestershire Hospitals NHS Foundation Trust | Study suspended pending further funding | Funding |
| NCT01271907 | Drosophila-generated CTL | Phase 2 | terminated | Jan 7, 2011 | National Cancer Institute (NCI) | Study was terminated due to withdrawal of CRADA partner. | Other (stated, no rule matched) |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT02321982 | Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery | N/A | withdrawn | Dec 22, 2014 | Dartmouth-Hitchcock Medical Center | Study topic is no longer being pursued by study team members | Other (stated, no rule matched) |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT00985140 | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | — | terminated | Sep 28, 2009 | Stanford University | Competing studies | Other (stated, no rule matched) |
| NCT01059305 | Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell… | Phase 2 | terminated | Jan 29, 2010 | M.D. Anderson Cancer Center | Lack of primary outcome efficacy. | Efficacy / futility |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | Phase 2 | terminated | Jul 10, 2012 | Adam Lerner | Poor enrollment | Enrollment / accrual |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With… | Phase 1 / Phase 2 | withdrawn | Sep 27, 2005 | Stanford University | not stated | Not stated |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | Phase 1 | withdrawn | May 2, 2016 | Anne Beaven, MD | Boehringer Ingelheim is discontinuing their volasertib development program | Other (stated, no rule matched) |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in… | Phase 2 | terminated | Mar 3, 2011 | National Cancer Institute (NCI) | Due to lack of clinical efficacy and lack of drug supply, trial was closed early and correlative… | Efficacy / futility |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT01468818 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | Phase 2 | terminated | Nov 10, 2011 | National Cancer Institute (NCI) | Study was closed prematurely due to slow and insufficient accrual. | Enrollment / accrual |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | — | terminated | Mar 16, 2012 | Stanford University | not stated | Not stated |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular… | Phase 1 / Phase 2 | terminated | Mar 11, 2013 | Spirig Pharma Ltd. | safety issues | Safety / toxicity |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | May 10, 2010 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT02061007 | Biomarker Correlates of Hypoxia in Metastatic Melanoma | Phase 2 | withdrawn | Feb 12, 2014 | H. Lee Moffitt Cancer Center and Research Institute | no accrual | Enrollment / accrual |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | Phase 1 / Phase 2 | terminated | Nov 8, 2010 | National Institutes of Health Clinical Center (CC) | Unexpected toxicities, likely due to TIL/IL-12 \& low % of durable responses. | Safety / toxicity |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | Phase 2 | terminated | Feb 7, 2008 | National Cancer Institute (NCI) | The study was terminated due to low accrual. | Enrollment / accrual |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | Phase 2 | terminated | Feb 11, 2008 | National Cancer Institute (NCI) | The study was terminated due to low accrual. | Enrollment / accrual |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | Phase 2 | terminated | Dec 20, 2011 | National Cancer Institute (NCI) | Due to slow accrual, the investigator decided to close the study. | Investigator |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous…(PXD101-CLN-6) | Phase 2 | terminated | Jan 11, 2006 | Valerio Therapeutics | Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient… | Enrollment / accrual |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma… | N/A | withdrawn | Jul 23, 2015 | Albert Einstein College of Medicine | no enrollment | Enrollment / accrual |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | withdrawn | May 1, 2013 | Stefan Schieke MD | not stated | Not stated |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | Phase 1 / Phase 2 | terminated | Aug 11, 2005 | University of Michigan | Slow enrollment | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00278018 | Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid… | Phase 1 / Phase 2 | terminated | Jan 18, 2006 | Hadassah Medical Organization | Because there were no responses | Other (stated, no rule matched) |
| NCT00994240 | Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC | N/A | terminated | Oct 14, 2009 | University of Wisconsin, Madison | slow enrollment, lack of funding | Enrollment / accrual |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | Phase 1 / Phase 2 | terminated | Jun 9, 2011 | National Cancer Institute (NCI) | Closed this protocol due to autoimmune toxicity. | Safety / toxicity |
| NCT01193036 | Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems | — | terminated | Sep 1, 2010 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous… | Phase 1 / Phase 2 | withdrawn | Nov 7, 2011 | OHSU Knight Cancer Institute | Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906… | Safety / toxicity |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | Phase 1 / Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00521092 | Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma | Phase 2 | withdrawn | Aug 27, 2007 | National Cancer Institute (NCI) | No participants enrolled. | Enrollment / accrual |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 17, 2018source: clinicaltrials